Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine - Seite 2
About FluGen:
FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases. The company’s lead candidate is M2SR, a supra-seasonal, live, single-replication,
intranasal flu vaccine. Unlike standard of care flu vaccines, M2SR stimulates mucosal, humoral, and cellular immunity. In an unprecedented challenge trial, M2SR demonstrated protection against
infection and illness across seven years of virus drift; and M2SR induces a durable antibody response with potential to cover an entire flu season and beyond. M2SR also has shown activity as a
vaccine vector for other respiratory vaccines and infectious diseases, including a COVID-19/flu combination. For more information about FluGen, Inc., please visit http://www.FluGen.com/.
Contacts:
Predictive Oncology Inc.
Theresa Ferguson, Senior Director of Marketing
Phone: (630) 566-2003
tferguson@predictive-oncology.com
Predictive Oncology Investor Relations
Tim McCarthy
LifeSci Advisors, LLC.
tim@lifesciadvisors.com
FluGen
Paul Radspinner
President & CEO
(608) 658-6095
pradspinner@flugen.com
Lesen Sie auch
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject
to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release
regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management
are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements
as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company
disclaims any intent or obligation to update these forward-looking statements.